Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain

被引:66
|
作者
Pechous, Roger
Celli, Jean
Penoske, Renee
Hayes, Stanley F.
Frank, Dara W.
Zahrt, Thomas C.
机构
[1] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA
[2] NIAID, Rocky Mt Labs, Lab Intracellular Parasites, NIH, Hamilton, MT 59840 USA
[3] NIAID, Rocky Mt Labs, Microscopy Core Unit, NIH, Hamilton, MT 59840 USA
关键词
D O I
10.1128/IAI.00666-06
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Francisella tularensis is a facultative intracellular pathogen and is the etiological agent of tularemia. It is capable of escaping from the phagosome, replicating to high numbers in the cytosol, and inducing apoptosis in macrophages of a variety of hosts. F. tularensis has received significant attention recently due to its potential use as a bioweapon. Currently, there is no licensed vaccine against F. tularensis, although a partially protective live vaccine strain (LVS) that is attenuated in humans but remains fully virulent for mice was previously developed. An F. tularensis LVS mutant deleted in the purMCD purine biosynthetic locus was constructed and partially characterized by using an allelic exchange strategy. The F. tularensis LVS Delta purMCD mutant was auxotrophic for purines when grown in defined medium and exhibited significant attenuation in virulence when assayed in murine macrophages in vitro or in BALB/c mice. Growth and virulence defects were complemented by the addition of the purine precursor hypoxanthine or by introduction of purMCDN in trans. The F. tularensis LVS Delta purMCD mutant escaped from the phagosome but failed to replicate in the cytosol or induce apoptotic and cytopathic responses in infected cells. Importantly, mice vaccinated with a low dose of the F. tularensis LVS Delta purMCD mutant were fully protected against subsequent lethal challenge with the LVS parental strain. Collectively, these results suggest that F. tularensis mutants deleted in the purMCD biosynthetic locus exhibit characteristics that may warrant further investigation of their use as potential live vaccine candidates.
引用
收藏
页码:4452 / 4461
页数:10
相关论文
共 50 条
  • [1] Generation and characterization of an attenuated mutant in a response regulator gene of Francisella tularensis live vaccine strain (LVS)
    Sammons-Jackson, Wendy L.
    McClelland, Karen
    Manch-Citron, Jean N.
    Metzger, Dennis W.
    Bakshi, Chandra Shekhar
    Garcia, Emilio
    Rasley, Amy
    Anderson, Burt E.
    [J]. DNA AND CELL BIOLOGY, 2008, 27 (07) : 387 - 403
  • [2] Formulation and Stabilization of Francisella tularensis Live Vaccine Strain
    Ohtake, Satoshi
    Martin, Russell A.
    Saxena, Atul
    Lechuga-Ballesteros, David
    Santiago, Araceli E.
    Barry, Eileen M.
    Vu Truong-Le
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (08) : 3076 - 3087
  • [3] Transcriptomic and Metabolic Responses to a Live-Attenuated Francisella tularensis Vaccine
    Goll, Johannes B.
    Li, Shuzhao
    Edwards, James L.
    Bosinger, Steven E.
    Jensen, Travis L.
    Wang, Yating
    Hooper, William F.
    Gelber, Casey E.
    Sanders, Katherine L.
    Anderson, Evan J.
    Rouphael, Nadine
    Natrajan, Muktha S.
    Johnson, Robert A.
    Sanz, Patrick
    Hoft, Daniel
    Mulligan, Mark J.
    [J]. VACCINES, 2020, 8 (03) : 1 - 23
  • [4] Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain
    Havlasová, J
    Hernychová, L
    Halada, P
    Pellantová, W
    Krejsek, J
    Stulík, J
    Macela, A
    Jungblut, PR
    Larsson, P
    Forsman, M
    [J]. PROTEOMICS, 2002, 2 (07) : 857 - 867
  • [5] Interaction of Francisella tularensis live vaccine strain with eukaryotic cells
    Krocova, Z
    Stulik, J
    Andelova, H
    Hartmanova, B
    Hernychova, L
    Hubalek, M
    Lenco, J
    Brychta, M
    Holicka, M
    Loudova, M
    Novosad, J
    Kroca, M
    Macela, A
    [J]. IMMUNOLOGY 2004: IMMUNODEFICIENCY, INFECTIOUS DISEASES, IMMUNOMODULATION, AND VACCINES, 2004, : 417 - 421
  • [6] Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease
    Green, M
    Choules, G
    Rogers, D
    Titball, RW
    [J]. VACCINE, 2005, 23 (20) : 2680 - 2686
  • [7] Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans
    El Sahly, H. M.
    Atmar, R. L.
    Patel, S. M.
    Wells, J. M.
    Cate, T.
    Ho, M.
    Guo, K.
    Pasetti, M. F.
    Lewis, D. E.
    Sztein, M. B.
    Keitel, W. A.
    [J]. VACCINE, 2009, 27 (36) : 4905 - 4911
  • [8] LIVE VACCINE STRAIN OF FRANCISELLA-TULARENSIS - INFECTION AND IMMUNITY IN MICE
    FORTIER, AH
    SLAYTER, MV
    ZIEMBA, R
    MELTZER, MS
    NACY, CA
    [J]. INFECTION AND IMMUNITY, 1991, 59 (09) : 2922 - 2928
  • [9] VACCINE POTENCIES OF LIVE VACCINE STRAIN OF FRANCISELLA-TULARENSIS AND ISOLATED BACTERIAL COMPONENTS
    HAMBLETON, P
    EVANS, CGT
    HOOD, AM
    STRANGE, RE
    [J]. BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY, 1974, 55 (04): : 363 - 373
  • [10] Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates
    Santiago, Araceli E.
    Mann, Barbara J.
    Qin, Aiping
    Cunningham, Aimee L.
    Cole, Leah E.
    Grassel, Christen
    Vogel, Stefanie N.
    Levine, Myron M.
    Barry, Eileen M.
    [J]. PATHOGENS AND DISEASE, 2015, 73 (06):